- Phase 2 MATISSE trial is evaluating IPH5201, an anti-CD39
blocking monoclonal antibody, in combination with Imfinzi
(durvalumab) and chemotherapy in early stage lung cancer
- IPH5201 is developed in collaboration with
AstraZeneca
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA)
(“Innate” or the “Company”) today announced the first
patient was dosed in MATISSE, a Phase 2 multicenter single-arm
study (NCT05742607), sponsored by Innate Pharma, evaluating
neoadjuvant and adjuvant treatment with IPH5201, an anti-CD39
blocking monoclonal antibody, in combination with durvalumab
(anti-PD-L1) and chemotherapy, in treatment-naïve patients with
resectable early stage non-small cell lung cancer (NSCLC).
The primary objectives of the study are to assess antitumor
activity of neoadjuvant treatment based on pathological complete
response (pCR) and safety.
Innate is responsible for conducting the study and shares study
costs with AstraZeneca (LSE/STO/Nasdaq: AZN). AstraZeneca supplies
clinical trial drugs.
Joyson Karakunnel, MD, MSc, FACP, Chief Medical Officer at
Innate Pharma “We are pleased to announce the dosing of a first
patient in this Phase 2 study conducted in collaboration with our
partner AstraZeneca. The study aims to assess the potential of
combining our IPH5201 drug candidate with durvalumab as neoadjuvant
treatment with chemotherapy and adjuvant treatment in patients
affected by resectable, early stage non-small cell lung cancer. If
this combination shows relevant anti-tumor activity while remaining
well tolerated, as observed in the previous Phase 1 study, it will
be a major step in the development of IPH5201 in this
indication.”
Fabrice Barlesi, MD, PhD, Professor of medicine at Paris
Saclay University, General Manager of Gustave Roussy and principal
investigator of the study added ”Despite the introduction of
novel treatment strategies, including immunotherapy with immune
checkpoint inhibitors, many patients with resectable, early stage
non-small cell lung cancer relapse following treatment leaving an
important medical need in this setting. IPH5201 is a potential
approach to reduce immunosuppression and promote antitumor immune
responses in the tumor microenvironment. We look forward to
continued enrollment and future results from this trial.”
More information about the Phase 2 MATISSE trial can be found on
clinicaltrials.gov.
Innate received a $5m milestone payment from AstraZeneca when
the decision was made to progress IPH5201 to a Phase 2 clinical
trial.
About IPH5201:
IPH5201 is a blocking antibody targeting the CD39
immunosuppressive pathway. CD39 is an extracellular enzyme that is
expressed in the tumor microenvironment, on both tumor infiltrating
cells and stromal cells in several cancer types. CD39 inhibits the
immune system by degrading adenosine triphosphate (ATP) into
adenosine monophosphate (AMP), which is then further degraded into
adenosine by CD73. By promoting the accumulation of
immune-stimulating ATP and preventing the production of
immune-suppressive adenosine, the blockade of CD39 may stimulate
anti-tumor activity.
About the Innate Pharma-AstraZeneca Multi-Term
Agreement:
In October 2018, Innate Pharma and AstraZeneca entered into a
development collaboration that included an option agreement for
IPH5201, an anti-CD39 blocking monoclonal antibody. As part of the
option agreement AstraZeneca paid Innate a $50m upfront payment for
the option to the exclusive license to co-develop and
co-commercialize IPH5201 and up to $825m in opt-in payments,
development and commercial milestones and high-single to
double-digit tiered royalties. Innate retains the right to receive
profit sharing within the EU.
About Innate Pharma
Innate Pharma S.A. is a global, clinical-stage biotechnology
company developing immunotherapies for cancer patients. Its
innovative approach aims to harness the innate immune system
through therapeutic antibodies and its ANKET®
(Antibody-based NK cell Engager
Therapeutics) proprietary platform.
Innate’s portfolio includes lead proprietary program lacutamab,
developed in advanced form of cutaneous T cell lymphomas and
peripheral T cell lymphomas, monalizumab developed with AstraZeneca
in non-small cell lung cancer, as well as ANKET® multi-specific NK
cell engagers to address multiple tumor types.
Innate Pharma is a trusted partner to biopharmaceutical
companies such as Sanofi and AstraZeneca, as well as leading
research institutions, to accelerate innovation, research and
development for the benefit of patients.
Headquartered in Marseille, France with a US office in
Rockville, MD, Innate Pharma is listed on Euronext Paris and Nasdaq
in the US.
Learn more about Innate Pharma at www.innate-pharma.com and
follow us on Twitter and LinkedIn.
Information about Innate Pharma shares
ISIN code
FR0010331421
Ticker code
Euronext: IPH Nasdaq: IPHA
LEI
9695002Y8420ZB8HJE29
Disclaimer on forward-looking information and risk
factors
This press release contains certain forward-looking statements,
including those within the meaning of the Private Securities
Litigation Reform Act of 1995. The use of certain words, including
“believe,” “potential,” “expect” and “will” and similar
expressions, is intended to identify forward-looking statements.
Although the company believes its expectations are based on
reasonable assumptions, these forward-looking statements are
subject to numerous risks and uncertainties, which could cause
actual results to differ materially from those anticipated. These
risks and uncertainties include, among other things, the
uncertainties inherent in research and development, including
related to safety, progression of and results from its ongoing and
planned clinical trials and preclinical studies, review and
approvals by regulatory authorities of its product candidates, the
Company’s commercialization efforts and the Company’s continued
ability to raise capital to fund its development. For an additional
discussion of risks and uncertainties which could cause the
company's actual results, financial condition, performance or
achievements to differ from those contained in the forward-looking
statements, please refer to the Risk Factors (“Facteurs de Risque")
section of the Universal Registration Document filed with the
French Financial Markets Authority (“AMF”), which is available on
the AMF website http://www.amf-france.org or on Innate Pharma’s
website, and public filings and reports filed with the U.S.
Securities and Exchange Commission (“SEC”), including the Company’s
Annual Report on Form 20-F for the year ended December 31, 2022,
and subsequent filings and reports filed with the AMF or SEC, or
otherwise made public, by the Company.
This press release and the information contained herein do not
constitute an offer to sell or a solicitation of an offer to buy or
subscribe to shares in Innate Pharma in any country.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230625819940/en/
Investors Innate
Pharma Henry Wheeler Tel.: +33 (0)4 84 90 32 88
Henry.wheeler@innate-pharma.fr
Media Relations
NewCap Arthur Rouillé Tel.: +33 (0)1 44 71 00 15
innate@newcap.eu
Innate Pharma (EU:IPH)
Graphique Historique de l'Action
De Avr 2024 à Mai 2024
Innate Pharma (EU:IPH)
Graphique Historique de l'Action
De Mai 2023 à Mai 2024